***Lactobacillus crispatus* DSM25988 as novel bioactive agent to co-aggregate *Streptococcus pyogenes* and to exclude it by binding to human cells**

A. Reiprich, L. Skalden, A. Raab, N. Bolotina and C. Lang*

Belano medical AG, Neuendorfstraße 19, 16761 Hennigsdorf, Germany; christine.lang@belanomedical.com

Received: 22 July 2021 / Accepted: 18 December 2021

© 2022 Wageningen Academic Publishers

RESEARCH ARTICLE

Abstract

Streptococcus pyogenes, a group A streptococcus, is the major bacterial pathogen responsible for acute bacterial infection of the human oropharynx and the causative agent of scarlet fever. Estimates of the global burden of *S. pyogenes* related diseases revealed 616 million cases of pharyngitis, and at least 517,000 deaths due to severe invasive diseases and sequelae. Here we describe *Lactobacillus crispatus* DSM25988 that was identified among hundreds of *Lactobacillus* strains (referring to all organisms that were classified as *Lactobacillaceae* until 2020) showing ability to prevent adhesion of *S. pyogenes* to Detroit 562 cells, and to exhibit a masking and co-aggregating effect on *S. pyogenes* *in vitro*. *L. crispatus* DSM25988 also inhibits invasion of cultured human epithelial pharyngeal cells by *S. pyogenes*. Competitive binding to fibronectin might be involved in the inhibition process. Antiviral activity of the *L. crispatus* DSM25988 cells were identified in an *in vitro* cell model demonstrating that *L. crispatus* effectively excludes viruses from epithelial cells using SARS-CoV2 proteins as a model. This finding points to the potential of DSM25988 to protect cells from virus infection. Biological activity is retained in heat treated cells. The heat-treated *Lactobacillus* strain was further developed into functional throat lozenges, wherein its biological activity is stably maintained in the formulation. Lozenges containing *L. crispatus* DSM25988 underwent testing in an uncontrolled, prospective user study in 44 subjects with symptoms of sore throat for a period of up to 14 days. The study data shows promising safety and efficacy of the medical device when used against symptoms of sore throat like scratchy feeling, hoarse voice and swallowing pain.

Keywords: group A streptococcus, SARS-CoV2, lactic acid bacteria, throat lozenges, user study

1. Introduction

Streptococcus pyogenes is a human bacterial pathogen with a tremendous virulence potential. It primarily colonises the upper respiratory pharyngeal mucosa (Walker *et al.*, 2014). Interactions with humans range from asymptomatic carriage over mild and superficial infections of mucosal membranes and skin up to systemic purulent toxic-invasive disease manifestations. *S. pyogenes* is the major bacterial pathogen responsible for acute infection of the human oropharynx and tonsils, and it is the causative agent of scarlet fever. *S. pyogenes* pharyngitis is commonly associated with sore throat, pain on swallowing, and fever. Estimates of the global burden of *S. pyogenes* related diseases revealed 616 million cases of pharyngitis and at least 517,000 deaths due to severe invasive diseases and

sequelae (Carapetis *et al.*, 2005). Although pharyngitis in the majority of cases primarily is caused by viral infections, *S. pyogenes* is responsible for 5-15% of sore throat visits in adults and 20-30% in children. The incidence peaks in children 5-15 years of age, and, in temperate climates, pharyngitis usually occurs in the winter and early spring. The risk of acute pharyngitis due to *S. pyogenes* among adults is higher for parents of school-age children and for those whose occupation brings them into close association with children (Lindbaek *et al.*, 2004). Asymptomatic carriage of *S. pyogenes* has been frequently noted among household contacts of patients with *S. pyogenes* pharyngitis. Moreover, *S. pyogenes* carriage by symptom-free health care workers has also been made responsible for nosocomial outbreaks (Danzmann *et al.*, 2013). In symptom-free children aged 2-4 years, carriage of 100 to 10,000 cfu/ml

S. pyogenes per nasopharyngeal swab has been detected (Thors *et al.*, 2016).

Much research has been done to reveal molecular interactions between *S. pyogenes* and its human host. Several cell surface proteins of *S. pyogenes* have been documented as being involved in pharyngeal adherence and colonisation during infection, including lipoteichoic acid, M-protein and collagen-like surface proteins Scl1 and Scl2. The adhesion proteins, and specifically the Scl proteins have been implicated in binding to a wide variety of factors on the surface of host pharyngeal cells, including fibronectin, laminin and collagen (Courtney *et al.*, 1986; Ellison *et al.*, 2020). A number of antibiotics have been shown to be effective in treating *S. pyogenes* pharyngitis. These include penicillin and its congeners (e.g. ampicillin and amoxicillin), as well as numerous cephalosporins, macrolides, and clindamycin (Shulman *et al.*, 2012). However, the use of antibiotics heavily disrupts the ecology of the human microbiota not only of the pharynx, but also of the gut, skin and other mucosal tissues. Dysbiosis of the microbiota has been associated with a large number of health problems and causally implicated in metabolic, immunological, and developmental disorders, as well as susceptibility to development of infectious diseases. The adverse effects of antibiotics on microbial succession, diversity, and resistance can last long past application, even for years (Langdon *et al.*, 2016).

Over the past decades, lactic acid bacteria have aroused interest for their use in prevention and treatment of multiple diseases owing to the health beneficial (probiotic) properties of some strains (Buckley *et al.*, 2018; Holz *et al.*, 2013, 2015). Mechanisms of action may include enhanced mucosal barrier function, direct antagonism with pathogens, inhibition of bacterial adherence and invasion capacity in the intestinal epithelium, boosting of the immune system and influence on the central nervous system (Shenderov *et al.*, 2020; Stavropoulou and Bezirtzoglou, 2020). Probiotics have also been considered an alternative to antibiotics (Kim *et al.*, 2015; Reid and Friendship, 2002). *Lactobacillus crispatus* is a commensal gram-positive lactic acid bacterium inhabiting the human vaginal and intestinal mucosa, and several strains are highly adhesive to different types of epithelial cells (He *et al.*, 2020). Phylogenetically, *L. crispatus* is closely related to *Lactobacillus acidophilus* and *Lactobacillus helveticus*, two of the most commonly used probiotics in food industry (You and Kim, 2020). *L. crispatus* has a long history of human consumption and has been identified in starter cultures for rye sourdough, in cheese, wine, sauerkraut and in whisky (Beganovic *et al.*, 2014; Henri-Dubernet *et al.*, 2008; Kačániová *et al.*, 2012; Meroth *et al.*, 2003; Van Beek and Priest, 2000). *L. crispatus* is classified as biosafety level 1, is Generally Regarded As Safe (GRAS), and is approved as a 'Qualified Presumption of Safety' (QPS) microorganism, which conforms with the safety requirements for a food or feed additive of the European Food Safety Authority

(EFSA) (Andreoletti *et al.*, 2008). Epidemiologic studies reveal a strong positive correlation between the presence of *L. crispatus* in the vaginal microbiota and reduced urogenital infection risk to bacterial, fungal and viral pathogens (Ngugi *et al.*, 2011; Wang *et al.*, 2019). Further, there is preclinical and clinical experimental evidence of *L. crispatus* reducing the urogenital and gastrointestinal infection risk towards multiple fungal, bacterial and viral pathogens (Horie *et al.*, 2002; Mousavi *et al.*, 2018; Parolin *et al.*, 2018; Stapleton *et al.*, 2011). Surface layer (S-layer) proteins, such as SlpA or CbsA are considered relevant for the antipathogenic activity of *L. crispatus*. These proteins support adherence of *L. crispatus* to epithelial cells of the cervix, thus sterically competing with, excluding or displacing pathogens from the mucosal surface (Abramov *et al.*, 2014; Chen *et al.*, 2007). Strain-specific adhesins from different *L. crispatus* strains could be identified as mucus-binding proteins. It appears that *L. crispatus* via its adhesins is able to interfere with fibronectin binding of pathogens to epithelial cells, thus reducing the colonisation of the pathogen (Ojala *et al.*, 2014). Moreover, *L. crispatus* has been described to adhere to fibronectin, laminin and to collagens I, IV and V, thus competing with pathogens for these proteins (Antikainen *et al.*, 2002). Besides this steric shielding effect, *L. crispatus* is also able to directly interact with pathogens on the basis of direct cell-cell contacts (Mousavi *et al.*, 2018; Parolin *et al.*, 2018).

Here, we describe the characterisation of heat-treated *L. crispatus* strain DSM25988 selected from a large lactic acid bacteria strain collection as a suitable lactic acid bacteria strain for the prevention of *S. pyogenes* adhesion to laropharyngeal epithelial cells, as well as a bioactive for the prevention and treatment of *S. pyogenes*-caused sore throat with its clinical application as a lozenge.

2. Materials and methods

Bacterial strains

Lactobacillus species strains from a proprietary strain collection were grown at laboratory scale and exposed to a systematic preclinical screening program as viable bacteria or after heat-treatment (OASSYS screening system; Organobalance GmbH, Berlin, Germany). The final hit was identified as *L. crispatus* by 16S rDNA sequence analysis. For whole genomic sequencing, DNA of *L. crispatus* DSM25988 was extracted (Leibniz Institute DSMZ GmbH, Braunschweig, Germany) and sequenced by Next Generation sequencing using PacBio RS technology (Rhoads and Au, 2015) followed by assembly of long high-quality reads to obtain the whole genome sequence (Eurofins Genomics GmbH, Ebersberg, Germany). Species-level taxonomic identification was performed (BaseClear BV, Leiden, the Netherlands). Potential antibiotic resistance genes and virulence factors were searched for by comparing

the aligned and annotated full genome sequence to the Comprehensive Antibiotic Resistance Database (CARD) (McMaster University, Ontario, Canada) and Virulence Factor Database (VFDB) (NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Beijing, China PR) databases in October 2019 (BaseClear BV). At lab scale, *L. crispatus* DSM 25988 was grown in MRS medium (De Man *et al.*, 1960) at 37 °C under anaerobic conditions if not described otherwise. *L. crispatus* DSM25988 was industrially manufactured by fermentation in yeast extract media at 37 °C, followed by heat treatment, cell separation and lyophilisation using maize starch for stabilisation (Lactosan GmbH & Co KG, Kapfenberg, Austria). *S. pyogenes* DSM11728 and *S. pyogenes* DSM20565 were obtained from the German Collection of Microorganisms and Cell Cultures GmbH (DSMZ, Braunschweig, Germany). Cells were grown in Todd-Hewitt-broth (Ellner *et al.*, 1966) at 37 °C, in a microaerobic atmosphere or at 5% CO₂ with 96% humidity if not described otherwise.

Co-aggregation

The test for co-aggregation activity of lactobacilli with *S. pyogenes* DSM11728 was adapted from Lang *et al.* (2010) and Holz *et al.* (2015) with the difference that the optical density (OD 600 nm) was adjusted to 2 (*S. pyogenes*), and to 1 (*Lactobacillus* species). *S. pyogenes* cells were stained with Vybrant® CFDA SE (Fisher Scientific GmbH, Hagen, Germany) adapted from Lang *et al.* (2010). For co-aggregation testing of salvans lozenges, one verum lozenge containing *L. crispatus* and one lozenge without lyophilised heat-treated *L. crispatus* (placebo), were dissolved in phosphate buffered saline (PBS) and subjected to the assay with unstained *S. pyogenes* cells.

Biofilm binding of *Lactobacillus* cells

In order to quantify binding of lactobacilli to *S. pyogenes* DSM11728 the optical density (OD₆₀₀) of washed *S. pyogenes* cells in PBS was adjusted to 1, transferred to 96 well microtiter plates for an overnight incubation at 37 °C to form a biofilm (Stepanović *et al.*, 2000). *Lactobacillus* cells grown overnight were stained with Vybrant CFDA SE. Aliquots of stained *Lactobacillus* cells were co-incubated with the *S. pyogenes* biofilm for 1 h and washed three times with PBS to remove unbound or loosely bound cells. Fluorescence was measured before and after incubation at 494 nm/512 nm and after each washing step with a Mithras Lb 940 multiplate reader (Berthold Technologies GmbH & Co.KG, Bad Wildbad, Germany).

Pharyngeal epithelial cell line invasion inhibition assay

Knowledge of adherence assays (Plant *et al.*, 2006) led to the approach of investigating the invasion inhibition of *S. pyogenes* by *L. crispatus*. Human pharynx carcinoma

epithelial cell line Detroit-562 cells were grown in supplemented Minimal Essential Medium (MEM) with Earle's salts at 37 °C, 5% CO₂, 95% humidity, plated in 24 well cell culture plates and cultivated again under identical conditions for 24 h. Non-adhering cells were removed. Washed bacterial cells were resuspended in MEM medium and the OD₆₀₀ was adjusted (*S. pyogenes* DSM20565 OD 0.2 and *L. crispatus* OD 1). *L. crispatus* suspension was pre-incubated with adhering Detroit 562 cells for 30 min at 37 °C, 5% CO₂, 95% humidity. *S. pyogenes* was added, and the cell culture plates were incubated again at 37 °C, 5% CO₂, 95% humidity for 30 min. Detroit 562 cells were then detached from the culture plates by adding cold water and placing the culture plate on an orbital shaker. Cells were suspended in PBS, plated onto neomycin blood agar and incubated at 37 °C under microaerophilic conditions. *S. pyogenes* colony counts were determined.

Biofilm reducing assay

The MBEC Assay® Biofilm Inoculator (Innovotech Inc., Edmonton, Canada) was used for biofilm density formation (Ceri *et al.*, 1999; Harrison *et al.*, 2010). Biofilm formation was tested with and without precoating of the polystyrene pegs with saliva. Pooled saliva from at least three human donors (Lee BioSolutions Inc., Maryland Heights, MO, USA) was sterile filtrated on the day of use to remove any microorganisms from the saliva. For saliva precoating, the peg lid was inserted into a microtiter plate with saliva in the respective microwells, and incubated at 37 °C for 1 h. Trypticase soy yeast extract medium (TSY), saliva and a 50:50 mixture of TSY and saliva were compared as growth media for establishing *S. pyogenes* biofilms. *S. pyogenes* was grown in TSY at 37 °C. In case of pre-treatment of *S. pyogenes* with *Lactobacillus* cells, *S. pyogenes* culture was incubated with lyophilised heat-treated manufactured *L. crispatus* (2 mg/ml final concentration) for 20 min with shaking at 120 rpm, then allowed to settle for 30 min. The supernatant and the untreated *S. pyogenes* culture were used for the biofilm assay on pegs and binding was analysed by determination of cfu/peg. In each case the untreated *S. pyogenes* culture was compared to the pre-treated *S. pyogenes* culture to determine the effect of *L. crispatus*.

Fibronectin binding assay

Fibronectin-coated 96 well microtiter-plates (Corning® BioCoat™ Fibronectin 96-well plates; Corning Inc, Corning, NY, USA) were adjusted to room temperature to investigate binding to immobilised fibronectin (Courtney *et al.*, 1986). Samples were applied and measured photometrically at wavelengths of 485 nm excitation and 528 nm emission (BioTek Instruments Inc., Winoosky, VT, USA). Cells were harvested and resuspended in PBS, OD₆₀₀ was adjusted. Samples of the lyophilised heat-treated manufacturing batches of *L. crispatus* were resuspended in PBS. Samples

were stained with CFDA SE (Fisher Scientific GmbH, Hagen, Germany or Biotium, Fremont, USA). PBS and maize starch samples were treated with CFDA in the same way as controls. For competitive binding assays the washed *S. pyogenes* DSM20565 was stained with CFDA SE (Biolegend, San Diego, CA, USA). Lyophilised heat-treated *L. crispatus* was suspended in PBS incubated at room temperature. Efficiency of reduced *S. pyogenes* fibronectin binding was calculated as relative binding inhibition in percent to the control *S. pyogenes* alone.

SARS-CoV2 neutralisation assay

SARS-CoV2 microneutralisation assay was performed at IBT Bioservices (Rockville, MD, USA) Manufactured *L. crispatus* (heat-treated, lyophilised) was suspended in PBS, pH was adjusted to 7.4. Vero cells seeded one day prior in black 96-well plates were incubated overnight. Two-fold serial dilutions ranging from 40 to 0.3 mg/ml were prepared in triplicate. The dilutions were then incubated with recombinant rVSV-SARS-CoV2 Spike for 1 h at 37 °C. After removing cell culture medium from the 96-well plates, the *L. crispatus*/virus mixtures were added to the Vero cells, and incubated for 24 h at 37 °C. Infection efficiency was measured by quantifying luciferase fluorescence; virus only and Vero cells only wells were added to calculate the 50% inhibition concentration (IC₅₀) using the XLFit dose response model.

Cytotoxicity assay

Cytotoxicity assay was performed at IBT Bioservices. Heat-treated, lyophilised *L. crispatus* was suspended in PBS, pH was adjusted to 7.4. Vero cells seeded one day prior in black 96-well plates were incubated overnight. Two-fold serial dilutions ranging from 40 to 0.3 mg/ml were prepared in triplicate. *L. crispatus* dilutions were incubated for 1 h at 37 °C and, after removing cell culture medium from the 96-well plates, were added to the Vero cells and incubated for 24 h at 37 °C. Cells only and medium only wells were also added. After incubation, cells were lysed for evaluation of the ATP content using the CellTiter-Glo® kit (Promega, Madison, WI, USA). Luciferase luminescence in relative light unit (RLU) was read and 50% cytotoxicity concentration (CC₅₀) was calculated using the XLFit dose response model.

Preparation of salvans lozenges

Lozenges ('salvans® Halspastillen') were manufactured using isomalt, marshmallow root extract, natural flavours, natural colorants and *L. crispatus* salvans (Dr. C. Soldan GmbH, Adelsdorf, Germany) and packaged in aluminium/PVC blisters (Captagel Pharma GmbH, Besigheim-Ottmarsheim, Germany). The product is indicated for the prevention and relief of sore throat symptoms in patients above 6 years of

age at risk of laryngeal infection caused by *S. pyogenes*, and certified as a substance-based, risk-class I medical device under GMP- and EN ISO 13485:2016 compliant manufacturing conditions (Nutrin GmbH, Hallerndorf, Germany). Conformity was evaluated and confirmed by the manufacturer on the basis of the manufacturing validation batch.

Salvans lozenges study

A social-media based, uncontrolled observational post market user follow-up study was launched in order to generate data on user acceptability, product safety and performance regarding the relief of sore throat symptoms in subjects prone to bacterial throat infection. Interested recipients were informed about the required actions and purpose of the study and data protection rights according to the European General Data Protection Regulation (EU) 2016/679 (GDPR; EC, 2016). Subjects willing to participate were asked to explicitly consent in writing to study participation and the collection, storage and use of their data for the purpose of the study. Via an electronic online questionnaire, subjects were requested to provide data on the frequency and duration of sore throat episodes over the last 5 years, the specification of common cold symptoms during these episodes, diagnosis of streptococcal angina by a general practitioner during this time, and prescription of antibiotics. Inclusion criteria were at least 2 annual sore throat episodes over the past 5 years, the occurrence of symptoms of bacterial throat infection or diagnosis of streptococcal angina by a general practitioner and a history of prescription of antibiotics. Exclusion criteria was the current use of antibiotics. The selected cohort of participants was provided with one package of lozenges (24 lozenges) and asked to complete an electronic baseline-questionnaire (baseline), as soon as they suffer from symptoms of sore throat, and another questionnaire after symptoms disappeared (follow-up). The data from the baseline and follow-up questionnaires was exported from the web application in Microsoft-Excel format, merged in Microsoft Excel (Microsoft, Redmond, WA, USA), quality checked and exported in csv-format. Descriptive data analysis was performed using the freeware PSPP. The following data were collected: demographics (age, gender), concomitant treatments, date of first lozenge application, occurrence of the common cold symptoms (irritated throat sensation, oropharyngeal redness, swallowing pain, hoarseness, running nose, cough (dry, productive), increased body temperature, fever, body aches, headache, ear pain, swollen lymph nodes, purulence, duration of symptoms at start of lozenge application, Visual Analog Scale (VAS) (0-10) assessment of throat pain, burning, swallowing pain, sensation of throat dryness, hoarseness, sensation of throat irritation, feeling of 'lump in the throat', inflammation, swelling, tight sensation, VAS (0-10) assessment of improvement of throat pain after

one lozenge (and speed of improvement), improvement of throat pain after one day of lozenge application (and number of lozenges).

3. Results

Selection of *Lactobacillus* strains co-aggregating with *Streptococcus pyogenes*

In the initial mass screening program, 798 lactobacilli strains ('lactobacilli' and *Lactobacillus* spec. designating all organisms that were classified as *Lactobacillaceae* until 2020) were evaluated for their binding capacity and binding strength to *S. pyogenes*. A subset of 89 (11.1%) lactobacilli strains showed medium to very strong binding. In follow-up investigations, the subset of 89 *Lactobacillus* strains was screened for their ability to co-aggregate with *S. pyogenes* in aqueous suspension. Thirty strains were identified to co-aggregate the *S. pyogenes* strain. Among these, a subset of five candidate strains was further analysed regarding efficiency of co-aggregation, fibronectin binding and binding to a pharyngeal epithelial cell line. Moreover, the candidates were analysed by 16s rRNA gene sequencing and whole genome analysis. The finally selected candidate was identified as *L. crispatus* (deposited under DSM25988). No transmissible antibiotic resistance genes or virulence factors were found when matching the genome of this strain to the CARD and VFDB databases. Living as well as heat-treated *L. crispatus* DSM 25988 cells were able to form large co-aggregates with *S. pyogenes* (Figure 1), involving multiple streptococci adhering to one *Lactobacillus* cell (microscopic analysis, data not shown).

Lactobacilli reduce adherence of *Streptococcus pyogenes* to human epithelial cells

In an adherence assay, we investigated if the pre-selected lactobacilli interfered with *S. pyogenes* binding to human epithelial host cells. Lactobacilli indeed reduced binding

of *S. pyogenes* in a competition assay, though in different degrees (Figure 2). *L. crispatus* DSM25988 (strain 3 in Figure 2) reduced binding of *S. pyogenes* by up to 22%.

Interference of *L. crispatus* (heat-treated lyophilised cells) with biofilm formation of *S. pyogenes* was analysed on saliva-coated or uncoated polystyrene pegs. Pre-incubation with *L. crispatus* DSM25988 significantly reduced *S. pyogenes* biofilm density by 1.35 and 0.85 log on the saliva-coating and uncoated polystyrene plates, respectively, indicating that *Lactobacillus* cells reduce biofilm formation and prevent binding of the pathogen.

Lactobacillus crispatus efficiently binds to fibronectin

To further characterise and understand the observed adherence inhibition of *S. pyogenes* by *L. crispatus* on human epithelial cells, we analysed fibronectin binding activities.

Figure 2. Invasion inhibition assay of selected lactobacilli against *Streptococcus pyogenes* on Detroit-562 cells. Lactobacilli from the screening cohort (strain 1-4) were pre-incubated for 30 min to human pharynx carcinoma epithelial cell line Detroit 562, *S. pyogenes* was added and incubated for 30 min. The control (labelled '*S. pyogenes*') is a human cell layer pre-incubated with phosphate buffered saline before incubation with *S. pyogenes*.

Figure 1. Co-aggregation of living and heat-treated *Lactobacillus crispatus* DSM25988 with *Streptococcus pyogenes* DSM11728. The results are shown compared to negative control (*L. crispatus*). *S. pyogenes* alone does not show any precipitation. Living and heat-treated *L. crispatus* DSM25988 induced comparable degrees of co-aggregate formation with *S. pyogenes*, and comparable *in vitro* efficacy in reducing planktonic *S. pyogenes* from the supernatant.

L. crispatus DSM25988 and heat-treated lyophilised *L. crispatus* DSM25988 were found to efficiently bind to fibronectin (Figure 3). DSM25988 (live cells as well as the heat-treated preparation) are able to bind to fibronectin as well as *S. pyogenes*, and that this binding is stable after three wash cycles.

Based on analysis of different *Lactobacillus* strains preselected for their ability to co-aggregate with *S. pyogenes*, *L. crispatus* DSM25988 (strain 3 in Figure 4) was selected for further analysis as it is most likely to exhibit a good exclusion activity against *S. pyogenes* on fibronectin binding (Figure 4).

Competitive exclusion experiments also showed that a heat-treated lyophilised preparation of *L. crispatus* reduced binding of *S. pyogenes* DSM20565 to fibronectin reliably and at a comparable efficiency as the viable cell preparation. The competitive exclusion activity increases with the number of heat-treated lyophilised *L. crispatus* cells used (Figure 5), and degree of exclusion can reach up to 80% under the conditions used.

***Lactobacillus crispatus* DSM 25988 neutralises SARS-CoV2 virus in a competitive binding assay**

As both bacterial and viral interactions with human epithelial cells predominantly occur via competitive binding to surface structures/receptors or direct fibronectin binding, we tested if *L. crispatus* DSM25988 exhibit activity in neutralise the SARS-CoV2 spike protein in a competitive binding experiment. Using a recombinant rVSV-Sars-CoV2 mutant and Vero cells, heat-treated *L. crispatus* cells were

Figure 3. Efficiency of binding of *Lactobacillus crispatus* DSM25988 and *Streptococcus pyogenes* to fibronectin coated plates. Fibronectin binding is detected for *L. crispatus* DSM25988 and heat-treated lyophilised *L. crispatus* DSM25988 to a similar level as for *S. pyogenes*. *S. pyogenes* and *L. crispatus* were stained with CFDA SE. Both baseline fluorescence (dark grey columns, showing the total fluorescence of the stained sample bound and non-bound) and fluorescence after the three washing steps (light grey columns, showing the bound cells after removal of non-binding cells) were measured. Results show the data from 8 datasets.

Figure 4. *Lactobacillus* cells reduce binding to fibronectin in a co-incubation-assay of *Lactobacillus* strains and *Streptococcus pyogenes* DSM20565. The diagram shows the percentage of adherent *S. pyogenes* cells in co-incubation with selected living and heat-treated *Lactobacillus* strains. The control shows *S. pyogenes* binding alone. Living, as well as heat-treated lactobacilli reduce the amount of *S. pyogenes* binding to fibronectin. Results show the data from 8 datasets.

Figure 5. Competitive binding of *Streptococcus pyogenes* to fibronectin in a co-incubation assay with heat-treated lyophilised *Lactobacillus crispatus* DSM25988 used at different concentrations. Data show concentration-dependent decrease in binding efficiency of *S. pyogenes* to fibronectin in a co-incubation assay with *L. crispatus* DSM25988. Results show the data from 8 datasets.

co-incubated and exclusion of virus protein binding was detected by fluorescence (luciferase assay). Neutralisation of rVSV-Sars-CoV2 mutant occurred at low concentrations while no cytotoxicity (CC50) of the preparation was detected (Table 1). Also, when the other tested *Lactobacillus* strains showed an even better neutralisation rate, it has to be considered that the cytotoxicity was much higher for these strains. Both parameters have to be seen in a context for further applications. Based on these results, *L. crispatus* showed the most promising results for further applications.

Table 1. Inhibition of rVSV-Sars-CoV2 mutant mean fluorescence signals in Vero cells by heat-treated lyophilised *Lactobacillus crispatus* DSM 25988 compared to non-related *Lactobacillus* strains (strains A and B). Results show data from 3 datasets.

Strain	Concentration of 50% neutralisation (mg/ml)	50% cytotoxicity concentration (mg/ml)
Heat-treated lyophilised <i>L. crispatus</i>	7.421	44.24
<i>Lactobacillus</i> strain A	5.946	9.614
<i>Lactobacillus</i> strain B	2.974	5.473

Verification of co-aggregation activity of *Lactobacillus crispatus* after formulation into the medical device salvans lozenges

The formulated heat-treated lyophilised *L. crispatus* DSM25988 in salvans lozenge was tested *in vitro* for co-aggregation activity (Figure 6). Furthermore, the placebo lozenge without heat-treated lyophilised *L. crispatus* (salvans) was co-incubated with *S. pyogenes* to determine background co-aggregation. While the salvans lozenge alone showed a slight background reaction (auto-aggregation), all other negative controls did not show any co-aggregation at all. Co-incubation of the salvans lozenge and *S. pyogenes* however showed a clear co-aggregation and interaction between *S. pyogenes* and the medical device salvans lozenges. This co-aggregation was clearly stronger than the background reactions. Co-aggregation of the salvans lozenge with the *S. pyogenes* is maintained after formulation.

Figure 6. Co-aggregation of *Streptococcus pyogenes* and *Lactobacillus crispatus* in formulated salvans medical device (MD) lozenge. A lozenge without *L. crispatus* (placebo) and salvans lozenge were investigated in co-aggregation assays. As negative controls *S. pyogenes* alone, placebo alone or salvans lozenge alone were used. A slight background reaction (auto-aggregation) of salvans lozenge is visible, but can be neglected in comparison to the co-aggregation of salvans lozenge and *S. pyogenes*.

Salvans lozenges user study

Subjects from a customer database who had previously given consent to receive information about new products, were contacted and informed about heat-treated lyophilised *L. crispatus* containing salvans throat lozenges and were asked to participate in a post-market user study with the certified medical device class I. In total, 147 subjects with a history of signs and symptoms or diagnoses indicating multiple bacterial throat infections during the last 5 years consented to participate in the prospective, uncontrolled patient reported outcome study. Each study subject was provided with one package of salvans throat lozenges and the link to electronic baseline and follow-up questionnaires, respectively. 86 subjects (58.5%) with an acute episode of throat irritation reported the baseline dataset (intention-to-treat dataset). Of these, 44 subjects (51%) also reported follow-up data (per protocol dataset).

This study is the first to evaluate the impact of *L. crispatus* DSM25988 formulated in salvans lozenges on throat infection symptoms. Details of the study population and the baseline characteristics are given in Supplementary Table S1. The overall symptom rating and the results on the subcategories are summarised in Table 2 and in Supplementary Table S2.

The overall VAS rating significantly decreases during the study and highlights an overall improvement. The largest decrease was seen in the swallowing pain, agonizing throat pain, dry throat and scratchy sensation. No side effects were reported in the study group.

Table 2. Longitudinal reporting of symptom severity.

	Baseline (n=44)	Follow-up (n=44)
Reported treatment duration (days)	–	8.35 (0, 17)
VAS symptom severity scoring ¹		
‘agonising throat pain’	4.82 (0, 9)	1.36 (0, 8)
‘burning’	3.33 (0, 8)	0.73 (0, 7)
‘swallowing pain’	4.38 (0, 9)	1.09 (0, 8)
‘dry throat’	5.67 (0, 10)	1.31 (0, 8)
‘hoarseness’	4.36 (0, 10)	1.36 (0, 7)
‘scratchy sensation’	5.60 (0, 10)	0.87 (0, 5)
‘lump in the throat’	2.56 (0, 10)	0.76 (0, 7)
‘inflamed throat’	3.31 (0, 10)	0.91 (0, 8)
‘swollen throat’	1.71 (0, 9)	0.69 (0, 9)
‘tightened feeling’	1.84 (0, 9)	0.60 (0, 7)

¹ Visual analog scale (VAS) symptoms severity ranged from 0 (not at all) to 10 (very strong). The brackets show minimum and maximum of all answers.

4. Discussion and conclusions

The main goal of this study was to identify and characterise a *Lactobacillus* strain that interacts with and co-aggregates *S. pyogenes*, the bacterial causative agent of throat infections, and to develop a suitable application device. We showed that selected *Lactobacillus* strains prevent adhesion and invasion of *S. pyogenes* to human epithelial pharyngeal cells. We identified strain *L. crispatus* DSM25988 as the best candidate to prevent *S. pyogenes* from binding to and invading human cells and as bioactive agent for the medical device as suitable application form.

Lactobacillus strains have long been used in food and dairy products. Many of those exhibit probiotic properties when applied as live cells and at adequate quantities and are proposed to be beneficial to human health, their main site of activity being the gastrointestinal tract (Silva *et al.*, 2020; Walter 2008). Lactobacilli with beneficial effects occur naturally in the human body and include strains of the species *Lactococcus lactis*, *Lactocaseibacillus paracasei* or *L. crispatus* (Abramov *et al.*, 2014; Pasolli *et al.*, 2020). When exploring and developing a novel strain for use in humans, several aspects have to be considered, among those being safety on the one hand and clear mode of action on the other hand (Doron and Snyderman, 2015; FAO/WHO, 2002; Melo Pereira *et al.*, 2018).

The safety characteristics are the strain's origin (healthy human microbiota), pathogenicity, and antibiotic resistance. *L. crispatus* is a naturally occurring *Lactobacillus* strain in the human body and is generally recognised as safe (GRAS-status). The genome analysis of *L. crispatus* DSM25988 showed that no antibiotic resistance genes or virulence factors are present, which is an additional safety aspect. Cytotoxicity has proved low. Activities of probiotic strains include epithelium adhesion ability, pathogen coaggregation and antimicrobial activity. The coaggregation properties of a probiotic strain with potential pathogens can be used as a screening marker for the selection of the probiotic strain for administration to humans (Melo Pereira *et al.*, 2018). Coaggregation enables the pathogen agglomeration with the probiotic cells, which results in the elimination of pathogen through natural body functions (faeces, saliva).

The activity of *L. crispatus* DSM25988 is partly based on its efficacy in binding to *S. pyogenes* cells. Co-aggregation has previously been described as a potent mode of action for bacterial interactions with the aim to remove single species from surfaces or bacterial communities. Recent examples include the co-aggregation of *Helicobacter pylori* in the gastric system, *Candida* spp. in the vaginal cavity or *Streptococcus mutans* in the oral cavity (Buckley *et al.*, 2018; Carmo *et al.*, 2016; Holz *et al.*, 2013, 2015). Co-aggregation which might also lead to 'masking' the microbial cell

surface binding molecules and sterically hinder binding of the pathogen to epithelial surface molecules may lead to detachment of target cells from the biofilm or from epithelial tissue, thus reducing inflammatory signals or biofilm stability. Additionally, the larger co-aggregate can more easily be removed from the oral cavity or other surfaces than single microbial cells.

L. crispatus DSM25988 also exhibits a binding activity to human cells, among others to cell surface structures like fibronectin. We propose that *L. crispatus* DSM25988 is able to directly interact with *S. pyogenes* and to bind to fibronectin which might exclude *S. pyogenes* from binding to epithelial cells. Interestingly, this latter feature makes *L. crispatus* DSM25988 a potential bioactive agent against viral particles that rely on fibronectin binding for cell invasion. We used SARS-CoV2 protein as a model system in this study to demonstrate this effect. More viruses, such as influenza virus, use fibronectin as binding partner to invade human cells (Greco *et al.*, 2002; Leung *et al.*, 2012). *In vivo* co-aggregation of group A streptococcus (GAS) streptococci, masking their surface sites ordinarily available for binding to epithelial cells, is suggested to reduce acute pharyngitis/tonsillitis risk by fostering clearance of planktonic GAS streptococci from the oral cavity by forming larger aggregate which are flushed from the oral cavity and throat by natural saliva flow. Manna *et al.* (2020) recently identified probiotic-derived lipopeptides as potential inactivating molecule for SARS-CoV 2 Spike protein and its human receptor ACE2. They hypothesised an immunomodulatory role of such metabiotic compounds. We propose that interaction of *L. crispatus* DSM25988 with fibronectin might be a therapeutic mechanism to exclude viruses from infection in human tissues as has previously been shown in the vaginal cavity (Abramov *et al.*, 2014; He *et al.*, 2020; Ojala *et al.*, 2014).

Different approaches had been used to identify potential aggregation-involved structures (Kojic *et al.*, 2011; Miljkovic *et al.*, 2015; Schachtsiek *et al.*, 2004; Younes *et al.*, 2012). Recent reviews summarise the diverse surface molecules found on *Lactobacillus* cells that are part of the pathogen and epithelium interactions (Muscariello *et al.*, 2020; Sengupta *et al.*, 2013). These include aggregation promoting factors in *Lactiplantibacillus plantarum*, *L. acidophilus* and *Lactobacillus gasseri* (Goh and Klaenhammer 2010). Which of those molecules are responsible for the observed activities in the *Lactobacillus* strain studied here, is part of our ongoing research.

We furthermore described the formulation of heat-treated *Lactobacillus crispatus* into lozenges (certified medical device class 1, MDD) in a user study. *S. pyogenes* (also known as group A β -haemolytic *Streptococcus* or GABHS) is the most common bacterial cause of acute sore throat. Antibiotics are still the most often prescribed therapy for

acute sore throat and are often unnecessary and ineffective in this setting, contributing to the growing problem of antibiotic resistance. Lozenges containing antiseptics have a broad range antibacterial activity which damages the oral microbiota as a severe side effect. Addressing microbiota management as an alternative to antimicrobial drugs has been proposed earlier and might be a valid paradigm change in treating infections (Humphreys and McBain 2019). Using inactivated, i.e. heat-treated cells of biologically active *Lactobacillus* cells is emerging as a new approach to deliver biological activity via metabolites or cell surface structures (Geraldo *et al.*, 2020; Shenderov *et al.*, 2020). Inactivated probiotics have been described to enhance host immunity or to protect against pathogens (Jeong *et al.*, 2020; Jia *et al.*, 2019).

A specific and targeted approach might prove a noteworthy alternative that helps to reduce the use of antibiotics and broad-spectrum antimicrobials in over the counter lozenges for sore throat application.

Supplementary material

Supplementary material can be found online at <https://doi.org/10.3920/BM2021.0103>.

Table S1. Baseline characteristics of salvans throat lozenges user group (intention to treat and per protocol cohort).

Table S2. Longitudinal reporting of treatment satisfaction and product safety at baseline and follow-up.

Conflict of interest

CL holds shares of Belano medical AG.

References

- Abramov, V., Khlebnikov, V., Kosarev, I., Bairamova, G., Vasilenko, R., Suzina, N., Machulin, A., Sakulin, V., Kulikova, N., Vasilenko, N., Karlyshev, A., Uversky, V., Chikindas, M.L. and Melnikov, V., 2014. Probiotic properties of *Lactobacillus crispatus* 2,029: homeostatic interaction with cervicovaginal epithelial cells and antagonistic activity to genitourinary pathogens. *Probiotics and Antimicrobial Proteins* 6: 165-176. <https://doi.org/10.1007/s12602-014-9164-4>
- Andreoletti, O., Budka, H., Buncic, S., Colin, P., Collins, J.D., De Koeijer, A., Griffin, J., Havelaar, A., Hope, J., Klein, G., Kruse, H., Magnino, S., López, A.M., McLauchlin, J., Nguyen-Thé, C., Noeckler, K., Noerrung, B., Prieto Maradona, M., Roberts, T., Vågsholm, I. and Vanopdenbosch, E., 2008. Scientific Opinion of the Panel on Biological Hazards on a request from EFSA on the maintenance of the QPS list of microorganisms intentionally added to food or feed. *EFSA Journal* 6: 923. <https://doi.org/10.2903/j.efsa.2008.923>
- Antikainen, J., Anton, L., Sillanpää, J. and Korhonen, T.K., 2002. Domains in the S-layer protein CbsA of *Lactobacillus crispatus* involved in adherence to collagens, laminin and lipoteichoic acids and in self-assembly. *Molecular Microbiology* 46: 381-394. <https://doi.org/10.1046/j.1365-2958.2002.03180.x>
- Beganović, J., Kos, B., Leboš Pavunc, A., Uroić, K., Jokić, M. and Šušković, J., 2014. Traditionally produced sauerkraut as source of autochthonous functional starter cultures. *Microbiological Research* 169: 623-632. <https://doi.org/10.1016/j.micres.2013.09.015>
- Buckley, M., Lacey, S., Doolan, A., Goodbody, E. and Seamans, K., 2018. The effect of *Lactobacillus reuteri* supplementation in *Helicobacter pylori* infection: a placebo-controlled, single-blind study. *BMC Nutrition* 4: 48. <https://doi.org/10.1186/s40795-018-0257-4>
- Carapetis, J.R., Steer, A.C., Mulholland, E.K. and Weber, M., 2005. The global burden of group A streptococcal diseases. *The Lancet Infectious Diseases* 5: 685-694. [https://doi.org/10.1016/S1473-3099\(05\)70267-X](https://doi.org/10.1016/S1473-3099(05)70267-X)
- Carmo, M.S., Noronha, F.M.F., Arruda, M.O., Costa, Ê.P.S., Bomfim, M.R.Q., Monteiro, A.S., Ferro, T.A.F., Fernandes, E.S., Girón, J.A. and Monteiro-Neto, V., 2016. *Lactobacillus fermentum* ATCC 23271 displays in vitro inhibitory activities against *Candida* spp. *Frontiers in Microbiology* 7: 1722. <https://doi.org/10.3389/fmicb.2016.01722>
- Ceri, H., Olson, M.E., Stremick, C., Read, R.R., Morck, D. and Buret, A., 1999. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. *Journal of Clinical Microbiology* 37: 1771-1776. <https://doi.org/10.1128/JCM.37.6.1771-1776.1999>
- Chen, X., Xu, J., Shuai, J., Chen, J., Zhang, Z. and Fang, W., 2007. The S-layer proteins of *Lactobacillus crispatus* strain ZJ001 is responsible for competitive exclusion against *Escherichia coli* O157:H7 and *Salmonella* Typhimurium. *International Journal of Food Microbiology* 115: 307-312. <https://doi.org/10.1016/j.ijfoodmicro.2006.11.007>
- Courtney, H.S., Ofek, I., Simpson, W.A., Hasty, D.L., Beachey, E.H., 1986. Binding of *Streptococcus pyogenes* to soluble and insoluble fibronectin. *Infection and Immunity* 53: 454-459. <https://doi.org/10.1128/iai.53.3.454-459.1986>
- Danzmann, L., Gastmeier, P., Schwab, F., and Vonberg, R.P., 2013. Health care workers causing large nosocomial outbreaks: a systematic review. *BMC Infectious Diseases* 13: 98. <https://doi.org/10.1186/1471-2334-13-98>
- De Man, J.C., Rogosa, M. and Sharpe, M.E., 1960. A medium for the cultivation of lactobacilli. *Journal of Applied Bacteriology* 23: 130-135. <https://doi.org/10.1111/j.1365-2672.1960.tb00188.x>
- Doron, S. and Snyderman, D.R., 2015. Risk and safety of probiotics. *Clinical Infectious Diseases* 60: 129-134. <https://doi.org/10.1093/cid/civ085>
- Ellison, A.J., Dempwolff, F., Kearns, D.B. and Raines, R.T., 2020. Role for cell-surface collagen of *Streptococcus pyogenes* in infections. *ACS Infectious Diseases* 10: 1836-1843. <https://doi.org/10.1021/acscinfecdis.0c00073>
- Ellner, P.D., Stoessel, C.J., Drakeford, E. and Vasi, F., 1966. A new culture medium for medical bacteriology. *American Journal of Clinical Pathology* 45: 502-504. https://doi.org/10.1093/ajcp/45.4_ts.502

- European Commission (EC), 2016. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation). Official Journal of the European Union L 119: 1-88.
- Food and Agriculture Organization of the United Nations/World Health Organization (FAO/WHO), 2002. Guidelines for the evaluation of probiotics in food. Report of a Joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food. Available at: <http://tinyurl.com/zdbrkeg>.
- Geraldo, B.M.C., Batalha, M.N., Milhan, N.V.M., Rossoni, R.D., Scorzoni, L. and Anbinder, A.L., 2020. Heat-killed *Lactobacillus reuteri* and cell-free culture supernatant have similar effects to viable probiotics during interaction with *Porphyromonas gingivalis*. Journal of Periodontal Research 55: 215-220. <https://doi.org/10.1111/jre.12704>
- Goh, Y.J. and Klaenhammer, T.R., 2010. Functional roles of aggregation-promoting-like factor in stress tolerance and adherence of *Lactobacillus acidophilus* NCFM. Applied and Environmental Microbiology 76: 5005-5012. <https://doi.org/10.1128/AEM.00030-10>
- Greco, G., Pal, S., Pasqualini, R. and Schnapp, L.M., 2002. Matrix fibronectin increases HIV stability and infectivity. Journal of Immunology 168: 5722-5729. <https://doi.org/10.4049/jimmunol.168.11.5722>
- Harrison, J.J., Stremick, C.A., Turner, R.J., Allan, N.D., Olson, M.E. and Ceri, H., 2010. Microtiter susceptibility testing of microbes growing on peg lids: a miniaturized biofilm model for high-throughput screening. Nature Protocols 5: 1236-1254. <https://doi.org/10.1038/nprot.2010.71>
- He, Y., Niu, X., Wang, B., Na, R., Xiao, B. and Yang, H., 2020. Evaluation of the inhibitory effects of *Lactobacillus gasseri* and *Lactobacillus crispatus* on the adhesion of seven common lower genital tract infection-causing pathogens to vaginal epithelial cells. Frontiers in Medicine 7: 284. <https://doi.org/10.3389/fmed.2020.00284>
- Henri-Dubernet, S., Desmasures, N. and Guéguen, M., 2008. Diversity and dynamics of lactobacilli populations during ripening of RDO Camembert cheese. Canadian Journal of Microbiology 54: 218-228. <https://doi.org/10.1139/W07-137>
- Holz, C., Alexander, C., Balcke, C., Moré, M., Auinger, A., Bauer, M., Junker, L., Grünwald, J., Lang, C. and Pompejus, M., 2013. *Lactobacillus paracasei* DSMZ16671 reduces mutans streptococci: a short-term pilot study. Probiotics and Antimicrobial Proteins 5: 259-263. <https://doi.org/10.1007/s12602-013-9148-9>
- Holz, C., Busjahn, A., Mehling, H., Arya, S., Boettner, M., Habibi, H. and Lang, C., 2015. Significant reduction in *Helicobacter pylori* load in humans with non-viable *Lactobacillus reuteri* DSM17648: a pilot study. Probiotics and Antimicrobial Proteins 7: 91-100. <https://doi.org/10.1007/s12602-014-9181-3>
- Horie, M., Ishiyama, A., Fujihira-Ueki, Y., Sillanpää, J., Korhonen, T.K. and Toba, T., 2002. Inhibition of the adherence of *Escherichia coli* strains to basement membrane by *Lactobacillus crispatus* expressing an S-layer. Journal of Applied Microbiology 92: 396-403. <https://doi.org/10.1046/j.1365-2672.2002.01539.x>
- Humphreys, G. and McBain, A., 2019. Antagonistic effects of *Streptococcus* and *Lactobacillus* probiotics in pharyngeal biofilms. Letters in Applied Microbiology 68: 303-312. <https://doi.org/10.1111/lam.13133>
- Jeong, M., Kim, J.H., Lee, J.S., Kang, S.D., Shim, S., Jung, M.Y., Yang, H., Byun, S. and Lee, K.W., 2020. Heat-killed *Lactobacillus brevis* enhances phagocytic activity and generates immune-stimulatory effects through activating the TAK1 pathway. Journal of Microbiology and Biotechnology 30: 1395-1403. <https://doi.org/10.4014/jmb.2002.02004>
- Jia, H., Ren, S. and Wang, X., 2019. Heat-killed probiotic regulates the body's regulatory immunity to attenuate subsequent experimental autoimmune arthritis. Immunology Letters 216: 89-96. <https://doi.org/10.1016/j.imlet.2019.10.009>
- Kačaniová, M., Hleba, L., Pochop, J., Kádasi-Horáková, M., Fikselová, M. and Rovná, K., 2012. Determination of wine microbiota using classical method, polymerase chain method and step one real-time PCR during fermentation process. Journal of Environmental Science and Health Part B 47: 571-578. <https://doi.org/10.1080/03601234.2012.665750>
- Kim, S.Y., Choi, D.J., and Chung, J., 2015. Antibiotic treatment for *Helicobacter pylori*: is the end coming? World Journal of Gastrointestinal Pharmacology and Therapeutics 6: 183-198. <https://doi.org/10.4292/wjgpt.v6.i4.183>
- Kojic, M., Jovicic, B., Strahinic, I., Begovic, J., Lozo, J., Veljovic, K. and Topisirovic, L., 2011. Cloning and expression of a novel lactococcal aggregation factor from *Lactococcus lactis* subsp. *lactis* BGKP1. BMC Microbiology 11: 265. <https://doi.org/10.1186/1471-2180-11-265>
- Lang, C., Böttner, M., Holz, C., Veen, M., Ryser, M., Reindl, A., Pompejus, M. and Tanzer, J.M., 2010. Specific *Lactobacillus*/mutans *Streptococcus* co-aggregation. Journal of Dental Research 89: 175-179. <https://doi.org/10.1177/0022034509356246>
- Langdon, A., Crook, N. and Dantas, G., 2016. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Medicine 8: 39. <https://doi.org/10.1186/s13073-016-0294-z>
- Leung, H.S.Y., Li, O.T.W., Chan, R.W.Y., Chan, M.C.W., Nicholls, J.M. and Poon, L.L.M., 2012. Entry of influenza A virus with a α 2,6-linked sialic acid binding preference requires host fibronectin. Journal of Virology 86: 10704-10713. <https://doi.org/10.1128/JVI.01166-12>
- Lindbaek, M., Høiby, E.A., Lermak, G., Steinsholt, I.M. and Hjortdahl, P., 2004. Predictors for spread of clinical group A streptococcal tonsillitis within the household. Scandinavian Journal of Primary Health Care 22: 239-243. <https://doi.org/10.1080/02813430410006729>
- Manna, S., Chowdhury, T., Chakraborty, R. and Mandal, S.M., 2020. Probiotics-derived peptides and their immunomodulatory molecules can play a preventive role against viral diseases including COVID-19. Probiotics and Antimicrobial Proteins 23: 1-13. <https://doi.org/10.1007/s12602-020-09727-7>
- Melo Pereira, G., Oliveira Coelho, B., Magalhaes, A.I., Thomaz-Socol, V., and Sokol, C.R., 2018. How to select a probiotic? A review and update of methods and criteria. Biotechnology Advances 36: 2060-2076. <https://doi.org/10.1016/j.biotechadv.2018.09.003>

- Mereth, C.B., Walter, J., Hertel, C., Brandt, M.J., and Hammes, W.P., 2003. Monitoring the bacterial population dynamics in sourdough fermentation processes by using PCR-denaturing gradient gel electrophoresis. *Applied and Environmental Microbiology* 69: 475-482. <https://doi.org/10.1128/AEM.69.1.475-482.2003>
- Miljkovic M., Strahinic I., Tolinacki M., Zivkovic M., Kojic S., Golic N., and Kojic M., 2015. AggLb is the largest cell-aggregation factor from *Lactobacillus paracasei* subsp. *paracasei* BGNJ1-64, functions in collagen adhesion, and pathogen exclusion *in vitro*. *PLoS ONE* 10: e0126387. <https://doi.org/10.1371/journal.pone.0126387>
- Mousavi, E., Makvandi, M., Teimoori, A., Ataei, A., Ghafari, S. and Samarbaf-Zadeh, A., 2018. Antiviral effects of *Lactobacillus crispatus* against HSV-2 in mammalian cell lines. *Journal of the Chinese Medical Association* 81: 262-267. <https://doi.org/10.1016/j.jcma.2017.07.010>
- Muscariello, L., De Siena, B. and Marasco, R., 2020. *Lactobacillus* cell surface proteins involved in interaction with mucus and extracellular matrix components. *Current Microbiology* 77: 3831-3841. <https://doi.org/10.1007/s00284-020-02243-5>
- Ngugi, B.M., Hemmerling, A., Bukusi, E.A., Kikuvu, G., Gikunju, J., Shiboski, S., Fredricks, D.N. and Cohen, C.R., 2011. Effects of BV-associated bacteria and sexual intercourse on vaginal colonization with the probiotic *Lactobacillus crispatus* CTV-05. *Sexually Transmitted Diseases* 38: 1020-1027. <https://doi.org/10.1097/OLQ.0b013e3182267ac4>
- Ojala, T., Kankainen, M., Castro, J., Cerca, N., Edelman, S., Westerlund-Wikström, B., Paulin, L., Holm, L. and Auvinen, P., 2014. Comparative genomics of *Lactobacillus crispatus* suggests novel mechanisms for the competitive exclusion of *Gardnerella vaginalis*. *BMC Genomics* 15: 1070. <https://doi.org/10.1186/1471-2164-15-1070>
- Parolin, C., Frisco, G., Foschi, C., Giordani, B., Salvo, M., Vitali, B., Marangoni, A. and Calonghi, N., 2018. *Lactobacillus crispatus* BC5 interferes with *Chlamydia trachomatis* infectivity through integrin modulation in cervical cells. *Frontiers in Microbiology* 9: 1-9. <https://doi.org/10.3389/fmicb.2018.02630>
- Pasolli, E., De Filippis, F., Mauriello, I.E., Cumbo, F., Walsh, A.M., Leech, J., Cotter, P.D., Segata, N. and Ercolini, D., 2020. Large-scale genome-wide analysis links lactic acid bacteria from food with the gut microbiome. *Nature Communications* 11: 2610. <https://doi.org/10.1038/s41467-020-16438-8>
- Plant, L., Sundqvist, J., Zughaier, S., Lövkvist, L., Stephens, D.S. and Jonsson, A., 2006. Lipooligosaccharide structure contributes to multiple steps in the virulence of *Neisseria meningitidis*. *Infection and Immunity* 74: 1360-1367. <https://doi.org/10.1128/IAI.74.2.1360-1367.2006>
- Reid, G., and Friendship, R., 2002. Alternatives to antibiotic use: probiotics for the gut. *Animal Biotechnology* 13: 97-112. <https://doi.org/10.1081/abio-120005773>
- Rhoads, A. and Au, K.F., 2015. PacBio sequencing and its application. *Genomics, Proteomics and Bioinformatics* 13: 278-289. <https://doi.org/10.1016/j.gpb.2015.08.002>
- Schachtsiek, M., Hammes, W.P. and Hertel, C., 2004. Characterization of *Lactobacillus cornyformis* DSM 20001T surface protein Cpf mediating coaggregation with and aggregation among pathogens. *Applied and Environmental Microbiology* 70: 7078-7085. <https://doi.org/10.1128/AEM.70.12.7078-7085.2004>
- Sengupta, R., Altermann, E., Anderson, R.C., McNabb, W.C., Moughan, P.J. and Roy, N.C., 2013. The role of cell surface architecture of *Lactobacilli* in host-microbe interactions in the gastrointestinal tract. *Mediators of Inflammation* 2013: 237921. <https://doi.org/10.1155/2013/237921>
- Shenderov, B.A., Sinita, A.V., Zakharchenko, M. and Lang, C., 2020. *Metabiotics*. Springer Nature, Berlin, Germany.
- Shulman, S.T., Bisno, A.B., Clegg, H.W., Gerber, M.A., Kaplan, E.L., Lee, G., Martin, J.M. and Van Beneden, C., 2012. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis. *Clinical Infectious Diseases* 55: e86-e102. <https://doi.org/10.1093/cid/cis629>
- Silva, D.R., Sardi, J.O., Souza Pitanguic, N., Roque, S.M., Barbosa da Silva, A.C. and Rosalen, P.L., 2020. Probiotics as an alternative antimicrobial therapy: current reality and future directions. *Journal of Functional Foods* 73: 104080. <https://doi.org/10.1016/j.jff.2020.104080>
- Stapleton, A.E., Au-Yeung, M., Hooton, T.M., Fredricks, D.N., Roberts, P.L., Czaja, C.A., Yarova-Yarovaya, Y., Fiedler, T., Cox, M. and Stamm, W.E., 2011. Randomized, placebo-controlled phase 2 trial of a *Lactobacillus crispatus* probiotic given intravaginally for prevention of recurrent urinary tract infection. *Clinical Infectious Diseases* 52: 1212-1217. <https://doi.org/10.1093/cid/cir183>
- Stavropoulou, E. and Bezirtzoglou, E., 2020. Probiotics in medicine: a long debate. *Frontiers in Immunology* 11: 2192. <https://doi.org/10.3389/fimmu.2020.02192>
- Stepanović, S., Vuković, D., Dakić, I., Savić, B. and Švabić-Vlahović, M., 2000. A modified microtiter-plate test for quantification of staphylococcal biofilm formation. *Journal of Microbiological Methods* 40: 175-179. [https://doi.org/10.1016/S0167-7012\(00\)00122-6](https://doi.org/10.1016/S0167-7012(00)00122-6)
- Thors, V., Morales-Aza, B., Pidwill, G., Vipond, I., Muir, P. and Finn, A., 2016. Population density profiles of nasopharyngeal carriage of 5 bacterial species in pre-school children measured using quantitative PCR offer potential insights into the dynamics of transmission. *Human Vaccines and Immunotherapeutics* 12: 375-382. <https://doi.org/10.1080/21645515.2015.1090069>
- Van Beek, S. and Priest, F.G., 2000. Decarboxylation of substituted cinnamic acids by lactic acid bacteria isolated during malt whisky fermentation. *Applied and Environmental Microbiology* 66: 5322-5328. <https://doi.org/10.1128/AEM.66.12.5322-5328.2000>
- Walker, M.J., Barnett, T.C., McArthur, J.D., Cole, J.N., Gillen, C.M., Henningham, A., Sriprakash, K.S., Sanderson-Smith, M.L. and Nizet, V., 2014. Disease manifestations and pathogenic mechanisms of group A *Streptococcus*. *Clinical Microbiology Reviews* 27: 264-301. <https://doi.org/10.1128/CMR.00101-13>
- Walter, J., 2008. Ecological role of lactobacilli in the gastrointestinal tract: implications for fundamental and biomedical research. *Applied and Environmental Microbiology* 74: 4985-4996. <https://doi.org/10.1128/AEM.00753-08>
- Wang, H., Ma, Y., Li, R., Chen, X., Wan, L. and Zhao, W., 2019. Associations of cervicovaginal lactobacilli with high-risk human papillomavirus infection, cervical intraepithelial neoplasia, and cancer: a systematic review and meta-analysis. *Journal of Infectious Diseases* 220: 1243-1254. <https://doi.org/10.1093/infdis/jiz325>

You, I. and Kim, E.B., 2020. Genome-based species-specific primers for rapid identification of six species of *Lactobacillus acidophilus* group using multiplex PCR. PLoS ONE 15: e0230550. <https://doi.org/10.1371/journal.pone.0230550>

Younes, J.A., Van der Mei, H.C., Van den Heuvel, E., Busscher, H.J. and Reid, G., 2012. Adhesion forces and coaggregation between vaginal staphylococci and lactobacilli. PLoS ONE 7: e36917. <https://doi.org/10.1371/journal.pone.0036917>